In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased significantly in value. Abbott received CE Mark approval for FreeStyle® Libre in September 2014 and for FreeStyle® 2 in October 2018. The company also launched FGM in the U.S. market in late 2017 and has expanded to numerous international
Throughout this medical market research, we analyzed over 90 diabetes companies across 16 countries and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts. While this MedSuite report contains all the Global Diabetes Monitoring, Treatment and Drug Delivery data and analysis, each of the market segments
In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased dramatically in value. The high level of growth was attributed to the commercial launch of FGM in late 2017. Abbott received FDA approval for FreeStyle® Libre in September 2017 and for FreeStyle® Libre 14 Day in July 2018. The
Continuous glucose monitoring (CGM) allows for a more accurate reading of how blood glucose levels fluctuate throughout the day by measuring interstitial glucose levels on a continuous basis and estimating blood glucose levels based on these readings.
The CGM system is typically made up of three components: a glucose sensor, transmitter and receiver. The sensor is inserted under the skin into the interstitial fluid and held with an adhesive. Sensors are typically sold in groups of four and are labeled for three to seven days of use, depending on the manufacturer. A transmitter takes the glucose reading from the sensor and wirelessly sends it to a small, hand-held receiver. If glucose levels are too low or high, the receiver warns the patient. Some manufacturers have even built-in a threshold audible alarm as a fixed safety feature when the patient approaches levels below 55 mg/dL, at which point the patient is still interactive but severely hypoglycemic.